MedTrace Logo

Lasix for the Prevention of De Novo Postpartum Hypertension

NCT04752475 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 82

Last updated 2024-12-13

Study results available
· View outcomes & findings →

Summary

Primary objective: To evaluate whether oral furosemide can help prevent de novo postpartum hypertension (new-onset high blood pressure after delivery) by reducing blood pressure after delivery in high-risk women.

Secondary objectives: To evaluate whether oral furosemide administered to high-risk women after delivery can reduce the frequency of postpartum hypertensive episodes, the need for antihypertensive therapy, the risk of postpartum preeclampsia, and the incidence of severe maternal morbidity.

Conditions

  • Postpartum Pregnancy-Induced Hypertension
  • Postpartum Preeclampsia
  • Hypertension, Pregnancy-Induced
  • Hypertension

Interventions

DRUG

Furosemide

Furosemide 20 mg pill taken daily for 5 days

OTHER

Placebo

Identical-appearing placebo pill taken daily for 5 days

Sponsors & Collaborators

Principal Investigators

  • Russell S. Miller, MD · Columbia University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-20
Primary Completion
2022-04-18
Completion
2022-05-28
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04752475 on ClinicalTrials.gov